Advances in Immunotherapy for Tuberculosis Treatment

被引：44

作者：

Churchyard, Gavin J. ^{[1
,2
,3
]}

Kaplan, Gilla ^{[4
]}

Fallows, Dorothy ^{[4
]}

Wallis, Robert S. ^{[5
]}

Onyebujoh, Philip ^{[6
]}

Rook, Graham A. ^{[7
]}

机构：

[1] Aurum Inst Hlth Res, ZA-2041 Johannesburg, South Africa

[2] Univ KwaZulu Natal, Nelson R Mandela Sch Med, ZA-4041 Durban, South Africa

[3] Univ Cape Town, Fac Hlth Sci, ZA-7935 Cape Town, South Africa

[4] Univ Med & Dent New Jersey, Publ Hlth Res Inst, Newark, NJ 07103 USA

[5] Pfizer Global Res & Dev, New London, CT 06320 USA

[6] WHO, Trop Dis Res, CH-1211 Geneva 27, Switzerland

[7] Royal Free & Univ Coll Med Sch, Ctr Infect Dis & Int Hlth, Windeyer Inst Med Sci, London W1P 7PP, England

来源：

CLINICS IN CHEST MEDICINE | 2009年 / 30卷 / 04期

关键词：

Tuberculosis; Immunotherapeutics; Antituberculous; Chemotherapy; Pulmonary infection; Immunopathology; TB treatment; NECROSIS-FACTOR-ALPHA; KILLED MYCOBACTERIUM-VACCAE; MULTIDRUG-RESISTANT TUBERCULOSIS; ADJUNCTIVE THALIDOMIDE THERAPY; PULMONARY TUBERCULOSIS; IMMUNE-RESPONSE; IFN-GAMMA; T-CELLS; ANTITUBERCULOSIS TREATMENT; ANTIINFLAMMATORY ACTIVITY;

D O I：

10.1016/j.ccm.2009.08.009

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Immunotherapies have the potential to improve the outcome in all patients with tuberculosis (TB) including those with multidrug-resistant (MDR)-TB and extensively drug-resistant (XDR)-TB. Immunotherapy for TB may shorten duration of treatment and reduce pathology in individuals cured by chemotherapy, potentially preventing recurrence. Currently none of the available candidate agents have proof of efficacy for use in MDR-TB or XDR-TB. Further development and evaluation of existing immunotherapeutic agents is required to identify an effective agent that can be used adjunctively with chemotherapy to improve treatment outcomes for drug-susceptible TB, MDR-TB, and XDR-TB. With a range of potential immunotherapeutics, some of which have been produced to good manufacturing practice (GMP) standards and are registered for other indications in humans, the immunotherapy option should no longer be ignored.

引用

页码：769 / +

页数：15

共 101 条

[31]

Hesseling AC, 2008, INT J TUBERC LUNG D, V12, P1376

[32] Helminth immunoregulation: The role of parasite secreted proteins in modulating host immunity [J].

Hewitson, James P. ;

Grainger, John R. ;

Maizels, Rick M. .

MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2009, 167 (01) :1-11

[33] PREDNISOLONE IN TREATMENT OF PULMONARY TUBERCULOSIS - A CONTROLLED TRIAL - FINAL REPORT TO THE RESEARCH COMMITTEE OF THE TUBERCULOSIS-SOCIETY-OF-SCOTLAND [J].

HORNE, NW .

BRITISH MEDICAL JOURNAL, 1960, 2 (DEC17) :1751-1756

[34] Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis [J].

Johnson, B ;

Bekker, LG ;

Ress, S ;

Kaplan, G .

GENETICS AND TUBERCULOSIS, 1998, 217 :99-111

[35] rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo [J].

Johnson, BJ ;

Bekker, LG ;

Rickman, R ;

Brown, S ;

Lesser, M ;

Ress, S ;

Willcox, P ;

Steyn, L ;

Kaplan, G .

TUBERCLE AND LUNG DISEASE, 1997, 78 (3-4) :195-203

[36] Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients [J].

Johnson, BJ ;

Estrada, I ;

Shen, Z ;

Ress, S ;

Willcox, P ;

Colston, MJ ;

Kaplan, G .

INFECTION AND IMMUNITY, 1998, 66 (06) :2426-2433

[37] Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis [J].

Johnson, JL ;

Ssekasanvu, E ;

Okwera, A ;

Mayanja, H ;

Hirsch, CS ;

Nakibali, JG ;

Jankus, DD ;

Eisenach, KD ;

Boom, WH ;

Ellner, JJ ;

Mugerwa, RD .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (02) :185-191

[38] Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis [J].

Johnson, JL ;

Kamya, RM ;

Okwera, A ;

Loughlin, AM ;

Nyole, S ;

Hom, DL ;

Wallis, RS ;

Hirsch, CS ;

Wolski, K ;

Foulds, J ;

Mugerwa, RD ;

Ellner, JJ .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) :1304-1312

[39] cAMP synthesis and degradation by phagosomes regulate actin assembly and fusion events: consequences for mycobacteria [J].

Kalamidas, Stefanos A. ;

Kuehnel, Mark P. ;

Peyron, Pascale ;

Rybin, Vladimir ;

Rauch, Susanne ;

Kotoulas, Othon B. ;

Houslay, Miles ;

Hemmings, Brian A. ;

Gutierrez, Maximiliano G. ;

Anes, Elsa ;

Griffiths, Gareth .

JOURNAL OF CELL SCIENCE, 2006, 119 (17) :3686-3694

[40] Mycobacterium tuberculosis growth at the cavity surface:: a microenvironment with failed immunity [J].

Kaplan, G ;

Post, FA ;

Moreira, AL ;

Wainwright, H ;

Kreiswirth, BN ;

Tanverdi, M ;

Mathema, B ;

Ramaswamy, SV ;

Walther, G ;

Steyn, LM ;

Barry, CE ;

Bekker, LG .

INFECTION AND IMMUNITY, 2003, 71 (12) :7099-7108

← 1 2 3 4 5 6 7 8 9 10 →